ReviewHeart failure reviews2026
International Utah cardiac recovery symposium (U-CARS) 2025:translational and basic science proceedings.
Review in Heart failure reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The 13th Annual Utah Cardiac Recovery Symposium (U-CARS) brought together experts from around the globe to discuss advances in cardiac research, with an emphasis on the role of adrenergic receptors in heart disease and the use of β-blockers. Presentations highlighted new insights into β-adrenergic signaling, revealing how precise modulation of these pathways could enhance therapeutic outcomes and reduce adverse effects in heart failure (HF). Dr. Michael Bristow offered a comprehensive review of three decades of gene expression studies in the human heart. His talk highlighted how molecular profiles of β-adrenergic receptor subtypes evolve during disease progression and respond to pharmacological intervention. By outlining shifts in adrenergic receptors, along with related signaling pathways, Dr. Bristow emphasized opportunities for developing more targeted β -blocker strategies. These refined approaches along with guideline directed medical therapies could optimize patient outcomes by leveraging the intricate interplay between gene expression changes and receptor pharmacology. Next, studies were presented to understand how cells within the heart communicate with one another and with other organ systems to maintain cardiovascular homeostasis. Presenters described emerging data on signaling crosstalk between cardiomyocytes and non-myocyte cell populations, such as fibroblasts and immune cells that shape cardiac remodeling. These findings suggest that targeted manipulation of intercellular communication may protect the heart from stress-induced damage. The final series of molecular discussions explored the expanding view of HF as a multisystem syndrome that involves complex interactions between cardiovascular, renal, and metabolic processes. Research was focused on how aberrant molecular signals not only drive disease within the heart but also affect kidney function and systemic metabolism, further exacerbating HF progression. Speakers highlighted the clinical potential of integrated therapeutic strategies that use approaches to target the heart alongside renal and metabolic pathways. Synergistic approaches could better address the root causes of acute and chronic HF, slowing or reversing disease progression by restoring balanced interorgan communication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.